摘要
Ipragliflozin(商品名:Suglat)为口服有效的钠依赖葡萄糖运载体2(sodium-glucose transporter 2,SGLT2)抑制剂,由日本Astellas和Kotobuki公司研发并于2014年1月在日本获得新药批准,可单独使用或与其他降糖药联合应用,治疗2型糖尿病,是日本首个获批的SGLT2抑制剂类药物。本文对其药理作用、药动学、临床研究及不良反应等方面作简要综述。
Ipragliflozin （ Suglat ）, an orally active sodium-glucose transporter 2 （SGLT2） inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical and received its first global approval for the treat- ment of type 2 diabetes mellitus in Japan in January 2014, used as monotherapy or in combination with another an- tihyperglycaemic agent. Ip viewed the pharmacology, ragliflozin is the first SGLT2 inhibitor to be approved in Japan. In this paper, we re- pharmacokinetics, clinical studies and adverse events of ipragliflozin.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第3期241-244,共4页
Chinese Journal of New Drugs
基金
天津市科技支撑计划重点项目类风湿性关节炎I类新药萝卜硫素类似物的开发(13ZCZDSY03000)
天津市科技支撑计划重点项目口服胰岛素胶囊的研制(13ZCZDSY02600)
